OSTEOARTROZ I KOMORBIDNOST': PROBLEMA VYBORA NESTEROIDNYKh PROTIVOVOSPALITEL'NYKh PREPARATOV


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The high frequency of comorbid conditions in osteoarthrosis (OA) defines considerable difficulties in the symptomatic treatment and the lack of its effectiveness. Differentiated approach to the appointment of nonsteroidal anti-inflammatory drugs (NSAIDs) in OA patients is based on an assessment of risk factors for complications of NSAID therapy. The article discusses the issues of different complications, presents the gradation of risk factors and approaches to their definition. The algorithm of selection of NSAIDs depending on the risk of complications is provided.

Full Text

Restricted Access

About the authors

N. V Chichasova

References

  1. Рациональная фармакотерапия ревматических заболеваний. Руководство для практикующих врачей, том III, глава 12. М., 2003.
  2. Bijlsma J.W., Berenbaum F., Lafeber F.P. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377:2115-26.
  3. Dawson J.I.L.I, Linsell L., Zondervan K., Rose P., Carr A., Randall T., Fitzpatrick R. Impact of persistent hip or knee pain overall health status in elderly People: a longitudinal population study. Arthr. Rheum. 2005;53:368-74.
  4. Lane N.E, Nevitt M.C., Hochberg M.C., Hung Y.Y., Palermo L. Progression of radiographic hip osteoarthritis over eight years in a community sample of elderly white women. Arthr. Rheum. 2004; 50: 1472-86.
  5. Nüesch E., Dieppe P., Reichenbach S., Williams S., Iff S., Jüni P. Disability and mortality in patients with osteoarthritis. BMJ. 2011; 342: d1165.
  6. Sokka T., Pincus T. Abstract presented during the American College of Rheumatology 2005 Scientific Sessions San Diego, California, № 1449.
  7. Martin G., Balshaw R., Conaghan P., et al. Inadequate pain relief in knee osteoarthritis: an early look at the survey in osteoarthritis real world therapies (SORT). Eur. J. Pain. 2011; 5(1 suppl.): 74.
  8. van Dijk G.V., Veenhof C., Schelleviset S., Hulsmans H., Bakker J.P., Arwert H., Dekker J.H., Lankhorst G.J., Dekker J. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMC Musculoskelet Disord. 2008; 9: 95.
  9. McAlindon T.E., Bannuru R.R., Sullivan M.C., Arden N.K., Berenbaum F., Bierma-Zeinstra S.M., Hawker G.A., Henrotin Y., Hunter D.J., Kawaguchi H., Kwoh K., LohmanderS., Rannou F., Roos E.M., Underwood M. OARSI Guielines for the non-surgical management of knee osteoarthritis. Ostearthr. Cartilage. 2014; 22: 363-88.
  10. Wills A.K., Black R., Cooper R., Coppack R.J., Hardy R., Martin K.R., Cooper C., Kuh D. Life course body mass index and risk of knee osteoarthritis at the age of 53 years: evidence from 1946 British cohort study. Ann. Rheum. Dis. 2012; 71: 655-60.
  11. Felson D.T. Osteoarthritis of knee. N. Engl. J. Med. 2006; 354: 841-48.
  12. Bruyere O., Cooper C.C., Pelletier J.-P., Branco J., Luisa Brandi M., Guillemin F., Hochberg M.C., Kanis J.A., Kvien T.K., Martel-PelletierJ., Rizzoli R., Silverman S., Reginster J.Y. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Sem. Arthr. Rheum. 2014; 44: 252-63.
  13. Lee C., Straus W.I., Balshaw R., Barlas S., Vogel S., Schnitzer T.J. A comparison on the efficacy and safety of nonsteroidal anti-inflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthr. Rheum. 2004; 51: 746-54.
  14. Zhang W., Nuki G., Moskowitz R.W., Abramson S., Altman R.D., Arden N.K., Bierma-Zeinstra S., Brandt K.D., Croft P., Doherty M., Dougados M., Hochberg M., Hunter D.J., Kwoh K., Lohmander L.S., Tugwell P. OARSI recommendation for the management of hip and knee osteoarthritis, part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr. Cartilage. 2010; 18: 476-99.
  15. Hochberg M.C., Altman R.D., April K.T., Benkhalti M., Guyatt G., McGowan J., Towheed T., Welch V., Wells G., Tugwell P. American College of Rheumatology 2012 recommendation for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012; 64: 465-74.
  16. Lanas A., Tomero J., Zamorano J.L. Assessment of gastrointestinal and cardiovascular risk in patients who require NSAID's: the LOGICA study. Ann. Rheum. Dis. 2010; 69: 1453-58.
  17. Lanas A., Garcia-Tell G., Armada B., Oteo-Alvaro A. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med. 2011; 9: 38. Published online 2011 Apr 14. doi: 10.1186/1741-7015-9-38 PMCID: PMC3101123.
  18. Laine L., Curtis S.P., Cryer B., Kaur A., Cannon C.P. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007; 369: 465-73.
  19. Deeks J., Smith L.A., Bradley M.D. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systemic review of randomized controlled trials. Br. Med. J. 2002; 325: 619-26.
  20. Каратеев А.Е., Коновалова Н.Н., Литовченко А.А., Ломарева Н.И.; Немцов Б.Ф., Раскина Т.А. Пешехонова Л.К., Насонов Е.Л. НПВП-ассоциированное заболевание желудочнокишечного тракта при ревматизме в России. Клин. мед. 2005; 5: 33-8.
  21. Unzueta A., Vargas H.E. Non-steroidal antiinflammatory drug-induced hepatotoxicity. Clin. Liver Dis. 2013; 17: 643-56.
  22. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J. Gastroenterol. 2010; 16: 5651-61.
  23. Traversa G., Bianchi C., Da Cas R., Abraha I., Menniti-Ippolito F., Venegoni M. Cohort study of hepatotoxity associated with nimesulide and other nonsteroidal anti-inflammatory drugs. BMJ. 2003; 327(7405): 18-22.
  24. Каратеев А.Е., Алексеева Л.И., Братыгина Е.А., Аширова Т.Б. Оценка частоты развития побочных эффектов при длительном применении нимесулидов в реальной клинической практике. РМЖ. 2009; 17: 1466-72.
  25. Oates J.A. Antagonism of antihypertensive drug therapy by nonsteroidal anti-inflammatory drugs. Hypertension. 1988; 11: 114-16.
  26. Мареев В.Ю. Реальна ли кардиологическая безопасность нестероидных противовоспалительных препаратов? Сердце. 2006; 2(4): 1-6.
  27. FDA. Safety Alerts for Human Medical Products. COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs NSAIDs. 2005. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm150314.htm
  28. EMEA. EMEA Press Release: European Medicines Agency Review Concludes Positive Benefit-risk Balance for Non-selective NSAIDs. CHMP 24 October 2006. http://www.emea.europa.eu/pdfs/human/press/pr/41313606.pdf Doc. Ref. EMEA/413136/2006.
  29. Graham D.J., Campen D., Hui R., Spence M., Cheetham C., Levy G., Shoor S., Ray W.A. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet. 2005; 365: 475-81.
  30. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н., Чичасова Н.В., Алексеева Л.И., Карпов Ю.А., Евсеев М.А., Кукушкин М.Л., Данилов А.Б., Воробьева О.В., Амелин А.В., Новикова Д.С., Драпкина О.М., Копенкин С.С., Абузарова Г.Р. Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике. М., 2015. 36 с.
  31. Moore A., Makinson G., Li C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthr. Res. Ther. 2013; 15: R6.
  32. Chan F.K., Lanas A., Schleiman J., Berger M.F., Nguyen H., Goldstein J.L. Celecoxib versus omeprasol and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010; 376: 173-79.
  33. Trelle S., Reichenbach S., Wandel S., Hildebrand P., Tschannen B., Villiger P.M., Egger M., Jüni P. Cardiovascular safety of nonsteroidal antiinflammatory drugs: network meta-analysis. BMJ. 2011; 342: 7086.
  34. Varas-Lorenzo C., Riera-Guardia N., Calingaet B., Castellsague J., Salvo F., Nicotra F., Sturkenboom M., Perez-Gutthann S. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Parmacoepid Drug Saf. 2013; 22: 559-70.
  35. Moore R.A., Derry S., Makinson G.T., McQuay H.J. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthr. Res. Ther. 2005; 7: R644-65.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies